Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 91


Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: A discrete event model study.

Attar A, Duru G, Roblin X, Savarieau B, Brunel P, Lamure M, Peyrin-Biroulet L.

Dig Liver Dis. 2019 Jan;51(1):112-119. doi: 10.1016/j.dld.2018.08.029. Epub 2018 Sep 5.


Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.

Amini-Adle M, Khanafer N, Le-Bouar M, Duru G, Dalle S, Thomas L.

BMC Cancer. 2018 Jul 3;18(1):705. doi: 10.1186/s12885-018-4618-9.


Evaluation of large clinically atypical vulvar pigmentation with RCM: atypical melanosis or early melanoma?

Theillac C, Cinotti E, Malvehy J, Ronger Savle S, Balme B, Robinson P, Perrot JL, Douchet C, Biron Schneider AC, Alos L, Garcia A, Barreiro A, Labeille B, Duru G, Dalle S, Thomas L, Debarbieux S.

J Eur Acad Dermatol Venereol. 2019 Jan;33(1):84-92. doi: 10.1111/jdv.15141. Epub 2018 Jul 12.


Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF?

Roblin X, Vérot C, Paul S, Duru G, Williet N, Boschetti G, Del Tedesco E, Peyrin-Biroulet L, Marc Phelip J, Nancey S, Flourie B.

Inflamm Bowel Dis. 2018 Apr 26. doi: 10.1093/ibd/izy111. [Epub ahead of print]


Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.

Roblin X, Boschetti G, Duru G, Williet N, Deltedesco E, Phelip JM, Peyrin-Biroulet L, Nancey S, Flourié B, Paul S.

Inflamm Bowel Dis. 2017 Nov;23(11):2048-2053. doi: 10.1097/MIB.0000000000001223.


Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.

Delaunay J, Martin L, Bressac-de Paillerets B, Duru G, Ingster O, Thomas L.

JAMA Dermatol. 2017 Nov 1;153(11):1122-1129. doi: 10.1001/jamadermatol.2017.2926.


Dermoscopic Features of Subungual Squamous Cell Carcinoma: A Study of 44 Cases.

Teysseire S, Dalle S, Duru G, Phan A, Debarbieux S, Poulhalon N, Thomas L.

Dermatology. 2017;233(2-3):184-191. doi: 10.1159/000479059. Epub 2017 Aug 23.


Surgical Treatment of Subungual Squamous Cell Carcinoma by Wide Excision of the Nail Unit and Skin Graft Reconstruction: An Evaluation of Treatment Efficiency and Outcomes.

Topin-Ruiz S, Surinach C, Dalle S, Duru G, Balme B, Thomas L.

JAMA Dermatol. 2017 May 1;153(5):442-448. doi: 10.1001/jamadermatol.2017.0014.


Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.

Roblin X, Duru G, Williet N, Del Tedesco E, Cuilleron M, Jarlot C, Phelip JM, Boschetti G, Flourié B, Nancey S, Peyrin-Biroulet L, Paul S.

Inflamm Bowel Dis. 2017 Jan;23(1):126-132. doi: 10.1097/MIB.0000000000000986.


Motivations of patients seeking supportive care for cancer from physicians prescribing homeopathic or conventional medicines: results of an observational cross-sectional study.

Danno K, Colas A, Freyer G, Guastalla JP, Duru G, Musial E, Libourel V, Fendler JP, Masson JL, Bordet MF.

Homeopathy. 2016 Nov;105(4):289-298. doi: 10.1016/j.homp.2016.09.001. Epub 2016 Oct 24.


New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma.

Teuma C, Perier-Muzet M, Pelletier S, Nouvier M, Amini-Adl M, Dijoud F, Duru G, Thomas L, Fouque D, Laville M, Dalle S.

Cancer Chemother Pharmacol. 2016 Aug;78(2):419-26. doi: 10.1007/s00280-016-3086-7. Epub 2016 Jul 1.


Homeopathic medical practice for anxiety and depression in primary care: the EPI3 cohort study.

Grimaldi-Bensouda L, Abenhaim L, Massol J, Guillemot D, Avouac B, Duru G, Lert F, Magnier AM, Rossignol M, Rouillon F, Begaud B; EPI3-LA-SER group.

BMC Complement Altern Med. 2016 May 4;16:125. doi: 10.1186/s12906-016-1104-2.


Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.

Faivre C, Villani AP, Aubin F, Lipsker D, Bottaro M, Cohen JD, Durupt F, Jeudy G, Sbidian E, Toussirot E, Badot V, Barbarot S, Debarbieux S, Delaporte E, Goegebeur G, Morel J, Nassif A, Duru G, Jullien D; French Society of Dermatology and Club Rheumatisms and Inflammation.

J Am Acad Dermatol. 2016 Jun;74(6):1153-9. doi: 10.1016/j.jaad.2016.01.018. Epub 2016 Mar 8.


Dermoscopy, a useful tool for general practitioners in melanoma screening: a nationwide survey.

Chappuis P, Duru G, Marchal O, Girier P, Dalle S, Thomas L.

Br J Dermatol. 2016 Oct;175(4):744-50. doi: 10.1111/bjd.14495. Epub 2016 Jun 30.


Economic impact of homeopathic practice in general medicine in France.

Colas A, Danno K, Tabar C, Ehreth J, Duru G.

Health Econ Rev. 2015 Dec;5(1):55. doi: 10.1186/s13561-015-0055-5. Epub 2015 Jul 8.


Utilization of psychotropic drugs by patients consulting for sleeping disorders in homeopathic and conventional primary care settings: the EPI3 cohort study.

Grimaldi-Bensouda L, Abenhaim L, Massol J, Guillemot D, Avouac B, Duru G, Lert F, Magnier AM, Rossignol M, Rouillon F, Begaud B; EPI3-LA-SER Group.

Homeopathy. 2015 Jul;104(3):170-5. doi: 10.1016/j.homp.2015.05.002. Epub 2015 Jun 10.


Quality of life assessment in cosmetics: specificity and interest of the international BeautyQol instrument.

Beresniak A, Auray JP, Duru G, Aractingi S, Krueger GG, Talarico S, Tsutani K, Dupont D, de Linares Y.

J Cosmet Dermatol. 2015 Sep;14(3):260-5. doi: 10.1111/jocd.12156. Epub 2015 Jul 2.


Dermoscopic Features of Onychomatricoma: A Study of 34 Cases.

Lesort C, Debarbieux S, Duru G, Dalle S, Poulhalon N, Thomas L.

Dermatology. 2015;231(2):177-83. doi: 10.1159/000431315. Epub 2015 Jun 20.


The value of childhood combination vaccines: From beliefs to evidence.

Maman K, Zöllner Y, Greco D, Duru G, Sendyona S, Remy V.

Hum Vaccin Immunother. 2015;11(9):2132-41. doi: 10.1080/21645515.2015.1044180. Review.

Supplemental Content

Loading ...
Support Center